English
















طباعة هذه الصفحة
الاسم: ا.م.د. / داليا محمد محمد داود
القسم: الصيدلة الاكلينيكية  
البريد الالكتروني: dalia.dawoud@pharma.cu.edu.eg  
الفاكس:
داخلي رقم.:
الغرفة:
السيرة الذاتية: ملف السيرة الذاتية
Scholar: https://scholar.cu.edu.eg/?q=ddawoud/publications
الموقع الالكتروني: https://scholar.cu.edu.eg/?q=ddawoud/publications
قائمة النشر - Publications Key journal publications:

1. Kostka K, Duarte-Salles T, Prats-Uribe A, Sena AG, Pistillo A, Khalid S, Lai LYH, Golozar A, Alshammari TM, Dawoud DM, et al. Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. Clin Epidemiol. 2022 Mar 22;14:369-384. doi: 10.2147/CLEP.S323292. PMID: 35345821; PMCID: PMC8957305.

2. Gomes M, Latimer N, Soares M, Dias S, Baio G, Freemantle N, Dawoud D, Wailoo A, Grieve R. Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. Pharmacoeconomics. 2022 Mar 25. doi: 10.1007/s40273-022-01141-x. Epub ahead of print. PMID: 35332434.

3. Dawoud D, Lamb A, Moore A, Bregman C, Rupniewska E, Paling T, Wolfram V, Lovett RES, Dent R. Capturing what matters: updating NICE methods guidance on measuring and valuing health. Qual Life Res. 2022 Mar 5. doi: 10.1007/s11136-022-03101-6. Epub ahead of print. PMID: 35247152.


4. Elvidge J, Summerfield A, Nicholls D, Dawoud D. Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations. Value Health. 2022 Feb 15:S1098-3015(22)00039-0. doi: 10.1016/j.jval.2022.01.001. Epub ahead of print. PMID: 35181207; PMCID: PMC8847103.

5. Morales DR, Ostropolets A, Lai L, Sena A, Duvall S, Suchard M, Verhamme K, Rjinbeek P, Posada J, Ahmed W, Alshammary T, Alghoul H, Alser O, Areia C, Blacketer C, Burn E, Casajust P, You SC, Dawoud D, et al.. Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. J Asthma. 2022 Feb 11:1-11. doi: 10.1080/02770903.2021.2025392. Epub ahead of print. PMID: 35012410.


6. Reyes C, Pistillo A, Fernández-Bertolín S, Recalde M, Roel E, Puente D, Sena AG, Blacketer C, Lai L, Alshammari TM, Ahmed WU, Alser O, Alghoul H, Areia C, Dawoud D et al. Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study. BMJ Open. 2021 Dec 22;11(12):e057632. doi: 10.1136/bmjopen-2021-057632. PMID: 34937726; PMCID: PMC8704062.

7. Elvidge J, Dawoud D. Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop. Pharmacoeconomics. 2021 Dec;39(12):1455-1463. doi: 10.1007/s40273-021-01097-4. Epub 2021 Oct 12. PMID: 34635993; PMCID: PMC8505112.


8. Dawoud D, Naci H, Ciani O, Bujkiewicz S. Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. BMJ. 2021 Sep 15;374:n2191. doi: 10.1136/bmj.n2191. PMID: 34526320.

9. Roel E, Pistillo A, Recalde M, Sena AG, Fernandez-Bertolin S, Aragon M, Puente D, Ahmed WU, Alghoul H, Alser O, Alshammari TM, Areia C, Blacketer C, Carter W, Casajust P, Culhane AC, Dawoud D, et al. Characteristics and outcomes of over 300,000 COVID-19 individuals with history of cancer in the United States and Spain. Cancer Epidemiol Biomarkers Prev. 2021 Jul 16:cebp.EPI-21-0266-E.2021. doi: 10.1158/1055-9965.EPI-21-0266. Epub ahead of print. PMID: 34272262.

10. Recalde M, Roel E, Pistillo A, Sena AG, Prats-Uribe A, Ahmed WU, Alghoul H, Alshammari TM, Alser O, Areia C, Burn E, Casajust P, Dawoud D et al. Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. Int J Obes (Lond). 2021 Jul 15:1–11. doi: 10.1038/s41366-021-00893-4. Epub ahead of print. PMID: 34267326; PMCID: PMC8281807.


11. Leckenby E, Dawoud D, Bouvy J, Jónsson P. The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review. Appl Health Econ Health Policy. 2021 Jul 13. doi: 10.1007/s40258-021-00665-1. Epub ahead of print. PMID: 34254275.


12. Prats-Uribe A, Sena AG, Lai LYH, Ahmed WU, Alghoul H, Alser O, Alshammari TM, Areia C, Carter W, Casajust P, Dawoud D, et al. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ. 2021 May 11;373:n1038. doi: 10.1136/bmj.n1038. Erratum in: BMJ. 2021 May 21;373:n1277. PMID: 33975825; PMCID: PMC8111167.

13. Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, Reich C, Duvall SL, Lynch KE, Matheny ME, Duarte-Salles T, Bertolin SF, Hripcsak G, Natarajan K, Falconer T, Spotnitz M, Ostropolets A, Blacketer C, Alshammari TM, Alghoul H, Alser O, Lane JCE, Dawoud DM, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021 Mar 16:keab250. doi: 10.1093/rheumatology/keab250. Epub ahead of print. PMID: 33725121; PMCID: PMC7989171.

14. Kent S, Burn E, Dawoud D, Jonsson P, Østby JT, Hughes N, Rijnbeek P, Bouvy JC. Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. Pharmacoeconomics. 2021 Mar;39(3):275-285. doi: 10.1007/s40273-020-00981-9. Epub 2020 Dec 18. PMID: 33336320; PMCID: PMC7746423.

15. Dawoud D, Chalkidou K, Sullivan R, Ruiz FJ, Adler A. USA stockpiling of remdesivir: How should the world respond? J Comp Eff Res. 2020 Dec;9(18):1243-1246. doi: 10.2217/cer-2020-0174. Epub 2020 Dec 4. PMID: 33274643; PMCID: PMC7717394.

16. Dawoud D, Soliman K. Cost effectiveness of antiviral treatments for pandemics and outbreaks of respiratory illnesses, including COVID-19: a systematic review of published economic evaluations. Value in Health. 23(11):1409-1422. doi: 10.1016/j.jval.2020.07.002. Epub 2020 Sep 6.

17. Lamb A, Dawoud D, Dent R, Elliott N, Adler AI. Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes. Lancet Neurol. 2020;19(4):290-291. doi:10.1016/S1474-4422(20)30060-0

18. Dawoud D. Emerging from the other end: Key measures for a successful COVID-19 lockdown exit strategy and the potential contribution of pharmacists [published online ahead of print, 2020 May 13]. Res Social Adm Pharm. 2020;10.1016/j.sapharm.2020.05.011. doi:10.1016/j.sapharm.2020.05.011


19. Hussain R, Dawoud DM, Babar Z-U-D. Drive-thru pharmacy services: A way forward to combat COVID-19 pandemic. Res Social Adm Pharm. (2020). Available from: http://www.sciencedirect.com/science/article/pii/S155174112030601X

20. Dawoud DM, El-Dahiyat F, Abojedi A, et al. Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in Arabic-Speaking countries [published online ahead of print, 2020 Jan 30]. Res Social Adm Pharm. (2020); S1551-7411(19)31086-1. doi:10.1016/j.sapharm.2020.01.018

21. Kharroubi SA, Beyh Y, Harake MDE, Dawoud D, Rowen D, Brazier J. Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population. Int J Environ Res Public Health. (2020);17(3):E1037. doi:10.3390/ijerph17031037

22. Lewis S, Glen J, Dawoud DM, Dias S, Cobb J, Griffin X et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. The Lancet Haemat. (2019); 6(10): e530 - e539. https://doi.org/10.1016/S2352-3026(19)30155-3

23. Stansby, G. , Donald, I. , Barry, P. , Dawoud, D. and Sharpin, C. NICE NG89 recommendations for extended pharmacological thromboprophylaxis – is it justified and is it cost effective: a rebuttal from the British Society for Haematology – response to Lester et al. Br J Haematol. (2019); https://doi:10.1111/bjh.16004

24. Dawoud, D, Haines, A, Wonderling, D., Ashe, J, Hill, J, Vari M, et al. Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review. PharmacoEconomics. (2019); DOI: https://doi.org/10.1007/s40273-019-00814-4

25. Lewis S, Glen J, Dawoud DM, Dias S, Cobb J, Griffin X et al. Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis. Value in Health. (2019); DOI: https://doi.org/10.1016/j.jval.2019.02.013

26. Dawoud, D, Smyth, M., Ashe, J., Strong, T., Wonderling, D., Hill, J et al. Effectiveness and cost effectiveness of pharmacist input at the ward level: a systematic review and meta-analysis. Res Social Adm Pharm. (2019); DOI: https://doi.org/10.1016/j.sapharm.2018.10.006

27. Shahzad Hasan S, How CS, Dawoud DM, Mohamed O, Baines D, Babar Z-U-D. (2019) Pharmaceutical policy reforms to regulate drug prices in Asia Pacific Region: The case of Australia, China, India, Malaysia, New Zealand and South Korea. Value in Health Regional Issues. 2019; 18:18-23.

28. Dawoud, DM, Wonderling, D, Glen, J, Lewis, S, Griffin, X, Hunt, BJ et al. Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service. Frontiers in Pharmacology. (2018); DOI: 10.3389/fphar.2018.01370

29. Keeney E, Dawoud D, Dias S. Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness and Cost-Effectiveness Analyses. PharmacoEconomics. (2018); 36 (5): 523–532.

30. Dawoud D, O’Mahony R, Wonderling D, Cobb J, Higgins B and Amiel S. Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. Value in Health. (2018); 21(2):176-184. doi: 10.1016/j.jval.2017.04.024

31. Dawoud D, Fenu E, Wonderling D, Higgins B and Amiel S. Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. Value in Health. (2017); 20(10): p1279–1287


32. Neilson J, O’Neill F, Dawoud D, Crean P. Intravenous fluids in children and young people: summary of NICE guidance. BMJ. (2015); 351:h6388

33. Amiel SA, Pursey N, Higgins B, Dawoud D; Guideline Development Group. Diagnosis and management of type 1 diabetes in adults: summary of updated NICE guidance. BMJ. (2015); 351:h4188. doi: 10.1136/bmj.h4188.

34. Hughes D, Charles J, Dawoud D, Edwards RT, Holmes E, et al. Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. Pharmacoeconomics. (2016); 34(5):447-61. doi: 10.1007/s40273-015-0371-y

35. Ridyard C, Dawoud D, Tuersley L, Hughes D. A systematic review of patients’ perspectives on the subcutaneous route of medication administration. The Patient- Patient-Centered Outcomes Research;(2016); 9(4):281-292
36. Sabry N, Farid S, Dawoud D. Antibiotic Dispensing in Egyptian Community Pharmacies: An Observational Study. Res Social Adm Pharm. (2014); 10(1):168-184.
37. Dawoud D. Time for more focus on pharmacoeconomics. Pharmaceutical Journal. (2013); 291 (6 July):11.
38. Hsia Y, Dawoud D, Sutcliffe A, Viner R, Kinra S, Wong I. Unlicensed use of metformin in children and adolescents in UK. British Journal of Clinical Pharmacology. (2012); 73(1):135-139.

Other Journal Publications

39. Elnady B, Elkhouly T, Dawoud NM, Desouky DE, Kewan HH, Dawoud DM, & Ritchlin, C. New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. Clinical Rheumatology. (2020); 10.1007/s10067-020-04957-0. Advance online publication. https://doi.org/10.1007/s10067-020-04957-0
40. Desselle SP, Chen AM, Amin M, Aslani P, Dawoud D, Miller MJ, Norgaard LS. Generosity, collegiality, and scientific accuracy when writing and reviewing original research. Res Social Adm Pharm. (2020); DOI: https://doi.org/10.1016/j.sapharm.2019.04.054
41. Desselle S, Amin M, Aslani P, Chen A, Dawoud DM, Miller M et al. Moving the needle—what does RSAP look for and what does it aim to do? Res Social Adm Pharm. (2019)
42. Dawoud D, Nina Barnett. Ward-based pharmacists are beneficial and cost-effective. The Pharmaceutical Journal Online, 2018, 29 October. DOI: 10.1211/PJ.2018.20205653
43. Dawoud N, Ayoub O, Essa N, Dawoud D. (2018) Myelodysplasia in a psoriasis patient receiving etanercept: Cause or coincidence? Indian Journal of Dermatology Venereology and Leprology. DOI: 10.4103/ijdvl.IJDVL_463_17
44. Sabry N, Farid S, Dawoud D. (2016) Drug related problems in cardiac children. Minerva Paediatrica. 68(2):89-95.
45. Sabry N, Dawoud D, Alansary A, Hounsome N. (2015) Outcomes of a protocol-based intervention to promote timely switching from intravenous to oral paracetamol: an interrupted time series analysis. Journal of Evaluation in Clinical Practice. 21(6):1081-8. doi: 10.1111/jep.12463.

46. Roberts E, Dawoud DM, Hughes DA, Cefai C. (2015) Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions. International Journal of Pharmacy Practice. 23(5):333-339. doi: 10.1111/ijpp.12173.

47. Ramanan A., Dick D., Benton D., Compeyrot-Lacassagne S., Dawoud D. et al. (2014) A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis (SYCAMORE Trial). Trials. 15:14
48. Dawoud D. (2013) Lack of Transparency needs to change. Pharmaceutical Journal, 290(23 Feb):200.
49. Alhyas L., Nielsen J, Dawoud D, Majeed A. (2013) Factors affecting the motivation of healthcare professionals providing care to Emiratis with type 2 diabetes. Journal of the Royal Society of Medicine Short Reports. 4(2):14
50. Dawoud D, Griffiths P, Maben J, Goodyer L, Greene R. (2011) Pharmacist supplementary prescribing: a step toward more independence? Research in Social and Administrative Pharmacy, 7(3): 246-256.
51. Bennett J, Dawoud D, Maben J. (2010) Effects of interruptions to nurses during medication administration. Nursing Management (Harrow), 16(9):22-23.
52. Griffiths P, Murrells T, Dawoud D, Jones S. (2010) Hospital admissions for asthma, diabetes and COPD: is there an association with practice nurse staffing? A cross sectional study using routinely collected data. BMC Health Services Research, 10:276. doi:10.1186/1472-6963-10-276
53. El-Assasy A, El-Gazayerly O, Dawoud D. (2004) Terbutaline sulphate wax microspheres. Bulletin of the Faculty of Pharmacy Cairo University, 42(2):29.
54. El-Assasy A, El-Gazayerly O, Dawoud D. (2003) Terbutaline sulphate hydrophilic matrix tablets. Egyptian Journal of Pharmaceutical Sciences, 43(1): 153-170.

Book Chapters

1- Dawoud D, Baines D. Economic evaluation and its types. In “Economic Evaluation of Pharmacy Services”. (2017) Editor Zaheer Ud-Din Babar. 1st Ed.; Academic Press, Elsevier.

2- Dawoud D. Discrete Choice Experiments. In “Encyclopaedia for Pharmacy Practice and Clinical Pharmacy” (2019) Editor Zaheer Ud-Din Babar. 1st Ed.; Academic Press, Elsevier.

3- Atif M, Malik I, Dawoud D, Gilani A, Babar ZUD. Essential medicine list, policies and the World Health Organisation. In “Encyclopaedia for Pharmacy Practice and Clinical Pharmacy” (2019) Editor Zaheer Ud-Din Babar. 1st Ed.; Academic Press, Elsevier. 1st Ed.; Academic Press, Elsevier.
حقوق النسخ © كل الحقوق محفوظة كلية الصيدلة جامعة القاهرة | القصر العيني, القاهرة, جمهورية مصر العربية |رقم بريدي 11562
للاتصال بنا | تليفون: 23639307 - 23624917 - 2363245 - (00202) | فاكس: 23628246